Johnson & Johnson skeleton $600 million assign related to Risperdal sales

<p>(Reuters) – <span>Johnson Johnson</span> pronounced on Friday it expects to take a special assign of about $600 million in a second entertain to accelerate pot for a intensity <span>settlement</span> of <span>civil lawsuits</span> associated to how it marketed <span>schizophrenia treatment</span> Risperdal and other drugs.</p>
<p> The large assign would also account intensity settlements for lawsuit involving selling of Invega, another JJ schizophrenia treatment, as good as Natrecor, a medicine for <span>congestive heart failure</span>.</p>
<p> The income being set aside would also assistance cover intensity settlements involving <span>Omnicare Inc</span>, a pharmacy user that provides medicines to patients in nursing homes and long-term caring facilities. Federal investigators have purported JJ done bootleg payments to Omnicare to squeeze and suggest Risp...